BPC-157, or Body Protection Compound-157, is a synthetic 15-amino-acid peptide based on a sequence identified in gastric juice. It is studied mainly in animal models for its proposed role in soft-tissue and gut healing, and is sold as a research chemical rather than an approved medicine.

What does research suggest about BPC-157?

Most evidence comes from rodent studies, which report accelerated healing of tendon, muscle, and gastrointestinal tissue, along with proposed effects on angiogenesis and growth-factor pathways. These preclinical results have not been replicated in controlled human clinical trials, so benefits in people remain unproven.

Is BPC-157 approved or legal?

BPC-157 is not an approved medicine in the EU or US and is not authorised for human use. It is sold only as a research chemical, and its legal status varies by jurisdiction. It is not a licensed treatment for any condition.

Human safety data is lacking because there are no substantial clinical trials. The purity, sterility, and dosing of research-grade material are unverified, adding further uncertainty. This information is educational and not a substitute for professional medical advice.

What are the reported side effects of BPC-157?

Because rigorous human studies are absent, side effects are only known anecdotally and include reported injection-site reactions. The long-term safety profile in humans is unknown.

How does BPC-157 compare to TB-500?

Both are peptides discussed in recovery and regeneration contexts and both lack robust human clinical trials. They are frequently compared online, but neither is an approved human medicine and evidence for each rests largely on animal and mechanistic data.

Why has BPC-157 become so popular despite limited human data?

Its visibility comes largely from social-media discussion, podcast mentions, and anecdotal recovery reports rather than from clinical evidence. The gap between strong online enthusiasm and the near-absence of controlled human trials is one of the most important things to understand about it. Popularity is not the same as proof of safety or efficacy. This page is educational and not medical advice.

How is BPC-157 different from TB-500, which it's often compared to?

Both are peptides discussed in the same recovery-and-regeneration context and are frequently mentioned together, but they have different origins and proposed mechanisms — BPC-157 derives from a gastric-juice protein fragment, while TB-500 is linked to Thymosin Beta-4 and actin regulation. Neither has robust controlled human trials supporting the recovery claims made for the research-market versions. Comparisons online should be read with that shared lack of evidence in mind.

Is BPC-157 "natural" because it comes from gastric juice?

This is a common misconception. Although its sequence is derived from a protein found in gastric juice, the compound sold and studied is a synthetic partial fragment, not a hormone that naturally circulates in the body at these amounts. "Derived from something natural" does not mean it is inherently safe or that its behaviour in humans is well characterised — human safety data remains lacking.

Where can I buy BPC-157 and compare vendors?

Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Recovery / Regeneration

Buy BPC-157 – Vendors, Prices, Testing and Evidence

Buy BPC-157

Also known as: Body Protection Compound-157 · PL 14736

Evidence grade C — Early / PreclinicalRisk flag

Short answer

A synthetic peptide fragment widely discussed for soft-tissue recovery. Human clinical evidence is very limited; most data is animal or mechanistic.

Where can you buy BPC-157?

Crystal Peptides. The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

What is known?

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. It is discussed in the community mainly in the context of tendon, ligament, and gut-related recovery.

What is not established?

Peer-reviewed human clinical trials are essentially absent. Claims about human recovery are extrapolated from animal work and personal reports.

Safety

Human safety data is lacking. Purity, sterility, and dosing of research-grade material are unverified. This is not a substitute for professional medical care.

Regulatory status

Not an approved medicine in the EU/US. Sold as a research chemical only; not authorised for human use.

Not medical advice. This educational reference is not diagnosis, treatment, prescribing, dosing or emergency guidance. Consult a qualified professional before making health-related decisions.

Regulatory or safety concern: This substance may be unapproved for human use, affect the hormonal system, or be subject to regulator or anti-doping restrictions. Check the cited evidence and rules in your jurisdiction.

Vendor comparison

Buy BPC-157: compare vendors

The table lists only product-specific offers that were checked and for which a real destination exists. Missing prices, quantities, stock and laboratory details are not inferred.

Vendor	Product	Documentation	Shipping	Checked	Action
Crystal Peptides Code PEPTIDES10 −10% · discount code details Sponsored	BPC-157 research product	Vendor-supplied data COA stated as available Not independently documented	Europe See the localized country store	Jul 18, 2026	View at vendor

Crystal Peptides

BPC-157 research product

Code PEPTIDES10 −10% · discount code details

What is it?

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. It is discussed in the community mainly in the context of tendon, ligament, and gut-related recovery.

Research and evidence

BPC-157 (Body Protection Compound-157, also cataloged as PL 14736) is a synthetic 15-amino-acid peptide derived from a protective protein sequence found in human gastric juice. It is discussed widely in fitness, recovery, and biohacking communities in the context of soft-tissue repair, particularly tendon, ligament, and gut-related healing. Despite that popularity, it is important to be clear about what BPC-157 actually is: a laboratory research compound, not an approved medicine. It is sold only as a research chemical and is not authorised for human use in the EU, US, or most other jurisdictions.

The reason BPC-157 draws so much interest is a substantial body of preclinical animal research. In rodent models, studies have reported accelerated healing of tendon, muscle, ligament, nerve, and gastrointestinal tissue, alongside proposed mechanisms such as promotion of angiogenesis (new blood-vessel formation), modulation of growth-factor and nitric-oxide signalling pathways, and effects on fibroblast activity in connective tissue. These findings are scientifically interesting and drive most of the online conversation, but they come almost entirely from animals and cell-based experiments. That distinction matters enormously when interpreting claims about human recovery.

The honest evidence picture is that peer-reviewed human clinical trials on BPC-157 are essentially absent. Reported benefits in people are extrapolated from animal work and anecdotal user reports rather than controlled studies, so efficacy in humans remains unproven. Human safety data is likewise lacking, and research-grade material carries additional unknowns around purity, sterility, and consistency because it is not manufactured to pharmaceutical standards. BPC-157 is an educational and research topic, not a validated treatment, and nothing here is medical advice or a substitute for professional care. This page summarizes what the current science does and does not support so readers can understand the compound accurately.

Evidence grade: C

Peer-reviewed human clinical trials are essentially absent. Claims about human recovery are extrapolated from animal work and personal reports. A body of rodent studies reports accelerated healing of tendon, muscle, and gut tissue. These results have not been replicated in controlled human trials.

Human evidence

Peer-reviewed human clinical trials are essentially absent. Claims about human recovery are extrapolated from animal work and personal reports.

Animal and preclinical evidence

A body of rodent studies reports accelerated healing of tendon, muscle, and gut tissue. These results have not been replicated in controlled human trials.

Proposed mechanisms

Proposed promotion of angiogenesis (new blood-vessel formation)
Discussed modulation of growth-factor and nitric-oxide pathways
Proposed effects on fibroblast activity in connective tissue

Safety concerns and known side effects

Human safety data is lacking. Purity, sterility, and dosing of research-grade material are unverified. This is not a substitute for professional medical care.

Injection-site reactions reported anecdotally
Unknown long-term safety profile

Regulatory status

Not an approved medicine in the EU/US. Sold as a research chemical only; not authorised for human use.

BPC-157 research timeline

Early 1990s
First described by researchers associated with the University of Zagreb, Croatia, as a synthetic 15-amino-acid partial sequence derived from a protein ("Body Protection Compound") found in gastric juice.
1990s–2000s
A growing body of rodent preclinical studies reports accelerated healing of tendon, muscle, and gastrointestinal tissue, forming most of the compound's evidence base.
2000s
Under the designation PL 14736, a stabilized form was explored in early-phase human research for inflammatory bowel conditions, though this did not lead to an approved medicine.
2010s
Preclinical literature expands and the compound spreads through fitness and biohacker communities, sold as a research chemical rather than a licensed drug.
Early 2020s
Online popularity surges for soft-tissue and gut recovery despite the continued absence of controlled human clinical trials.
2023
The US FDA flagged BPC-157 among bulk substances not permitted for pharmacy compounding, citing insufficient safety data for human use.

Frequently asked questions about BPC-157

What is BPC-157?: BPC-157, or Body Protection Compound-157, is a synthetic 15-amino-acid peptide based on a sequence identified in gastric juice. It is studied mainly in animal models for its proposed role in soft-tissue and gut healing, and is sold as a research chemical rather than an approved medicine.
What does research suggest about BPC-157?: Most evidence comes from rodent studies, which report accelerated healing of tendon, muscle, and gastrointestinal tissue, along with proposed effects on angiogenesis and growth-factor pathways. These preclinical results have not been replicated in controlled human clinical trials, so benefits in people remain unproven.
Is BPC-157 approved or legal?: BPC-157 is not an approved medicine in the EU or US and is not authorised for human use. It is sold only as a research chemical, and its legal status varies by jurisdiction. It is not a licensed treatment for any condition.
Is BPC-157 safe?: Human safety data is lacking because there are no substantial clinical trials. The purity, sterility, and dosing of research-grade material are unverified, adding further uncertainty. This information is educational and not a substitute for professional medical advice.
What are the reported side effects of BPC-157?: Because rigorous human studies are absent, side effects are only known anecdotally and include reported injection-site reactions. The long-term safety profile in humans is unknown.
How does BPC-157 compare to TB-500?: Both are peptides discussed in recovery and regeneration contexts and both lack robust human clinical trials. They are frequently compared online, but neither is an approved human medicine and evidence for each rests largely on animal and mechanistic data.
Why has BPC-157 become so popular despite limited human data?: Its visibility comes largely from social-media discussion, podcast mentions, and anecdotal recovery reports rather than from clinical evidence. The gap between strong online enthusiasm and the near-absence of controlled human trials is one of the most important things to understand about it. Popularity is not the same as proof of safety or efficacy. This page is educational and not medical advice.
How is BPC-157 different from TB-500, which it's often compared to?: Both are peptides discussed in the same recovery-and-regeneration context and are frequently mentioned together, but they have different origins and proposed mechanisms — BPC-157 derives from a gastric-juice protein fragment, while TB-500 is linked to Thymosin Beta-4 and actin regulation. Neither has robust controlled human trials supporting the recovery claims made for the research-market versions. Comparisons online should be read with that shared lack of evidence in mind.
Is BPC-157 "natural" because it comes from gastric juice?: This is a common misconception. Although its sequence is derived from a protein found in gastric juice, the compound sold and studied is a synthetic partial fragment, not a hormone that naturally circulates in the body at these amounts. "Derived from something natural" does not mean it is inherently safe or that its behaviour in humans is well characterised — human safety data remains lacking.
Where can I buy BPC-157 and compare vendors?: Use the vendor comparison on this page. It shows only checked, product-specific links and identifies vendor claims, independent documentation and affiliate relationships separately. Availability and legal status can vary by country.

Common discussion areas

Tendon and ligament recoveryGut discomfortPost-injury reports

Compare BPC-157

BPC-157 vs TB-500 / Thymosin Beta-4 BPC-157 vs GHK-Cu

Sources

Editorial review and transparency

Written by: peptides.cx Editorial Team
Scientific reviewer: No named medical reviewer is currently assigned
Last editorial review: June 1, 2026
Last vendor check: July 18, 2026
Review method: Source review, claim verification, vendor-data separation and regulatory-context review.
Commercial disclosure and conflicts: Vendor relationships do not determine evidence or safety ratings. No named reviewer conflict is recorded because no named reviewer is assigned.

Editorial policy →Evidence grade →Vendor methodology →

Related on peptides.cx

Library →Vendor quality checklist →Safety →Affiliate code: PEPTIDES10